Breaking News Instant updates and real-time market news.

SNY

Sanofi

$44.78

0.65 (1.47%)

, RGLS

Regulus

$1.87

0.01 (0.54%)

07:51
11/06/18
11/06
07:51
11/06/18
07:51

Regulus amends and restructures agreement with Sanofi

Regulus Therapeutics (RGLS) announced that it has amended and restructured its Collaboration and License Agreement with Sanofi (SNY). Under the terms of the Amendment, Regulus has granted Sanofi a worldwide exclusive license to develop and commercialize its investigational drug, targeting miR-21 for all indications, including Alport syndrome. Under the Amendment, Sanofi will assume all future costs and development activities associated with the advancement of RG-012, currently in Phase 2 for Alport syndrome. Under the terms of the Amendment, Regulus is eligible to receive approximately $7M in upfront and material transfer payments. Regulus is also eligible to receive up to $40M in development milestone payments. In addition, Sanofi will reimburse Regulus for certain out-of-pocket transition activities and assume Regulus' upstream license royalty obligations.

SNY

Sanofi

$44.78

0.65 (1.47%)

RGLS

Regulus

$1.87

0.01 (0.54%)

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

SNY Sanofi
$44.78

0.65 (1.47%)

11/01/18
11/01/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nutrisystem (NTRI) upgraded to Outperform from Market Perform at Barrington and to Neutral from Underperform at DA Davidson. 2. SeaWorld (SEAS) upgraded to Overweight from Sector Weight at KeyBanc with analyst Brett Andress saying de-risked expectations following the Q3 pre-announcement create an attractive entry point, as he sees further upside to shares, with his confidence in the company's turnaround bolstered by additional evidence of both a brand and business in recovery mode. 3. Sanofi (SNY) upgraded to Equal Weight from Underweight at Barclays with analyst Emmanuel Papadakis saying he sees a more balanced risk/reward profile at current share levels. 4. Asur (ASR) upgraded to Overweight from Neutral at JPMorgan with analyst Fernando Abdalla citing valuation. 5. Wex (WEX) upgraded to Outperform from Market Perform at Wells Fargo. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/01/18
LEHM
11/01/18
UPGRADE
LEHM
Equal Weight
Sanofi upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Emmanuel Papadakis upgraded Sanofi to Equal Weight and raised his price target for the shares to EUR 80 from EUR 68 following the company's Q3 results. The analyst sees a more balanced risk/reward profile at current share levels.
10/25/18
WELS
10/25/18
NO CHANGE
WELS
Wells Fargo says Trump speech today won't be end of drug pricing proposals
Wells Fargo analyst David Maris notes that Politico and other media outlets are reporting that President Donald Trump will propose several new initiatives to address high drug prices when he speaks later today at the U.S. Department of Health and Human Services. Maris thinks Trump's focus will be on how other countries are "freeloading" on U.S. innovation with lower negotiated pricing, stating that news reports make it appear that the administration is targeting the industry for action, rather than other countries to raise their spending. While Maris acknowledges the timing of the speech being near the mid-term elections, he believes these proposals are simply the follow-though of earlier promises. He also expects this is not the end of proposals to address the issue of U.S. drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/23/18
WOLF
10/23/18
INITIATION
WOLF
Peer Perform
Sanofi reinitiated with a Peer Perform at Wolfe Research
RGLS Regulus
$1.87

0.01 (0.54%)

07/10/18
07/10/18
DOWNGRADE
Target $1

Neutral
Regulus downgraded to Neutral at Wedbush
As previously reported, Wedbush analyst Liana Moussato downgraded Regulus (RGLS) to Neutral from Outperform after he extended developmental timelines due to partnership restructuring with Sanofi (SNY) pausing clinical enrollment for RG-012 and unexpected mouse toxicity observations delaying clinical progress for RGLS4326. The analyst also lowered his price target on Regulus shares to $1 from $3.
07/10/18
WEDB
07/10/18
DOWNGRADE
WEDB
Neutral
Regulus downgraded to Neutral from Outperform at Wedbush
07/06/18
WELS
07/06/18
NO CHANGE
Target $0.5
WELS
Market Perform
Regulus price target lowered to 50c from $1.50 at Wells Fargo
Wells Fargo analyst Jim Birchenough lowered his price target for Regulus Therapeutics to the company's approximate cash level of 50c following the interruption of the Phase 1 study of anti-miR therapeutic RGLS4326 in autosomal dominant polycystic kidney disease due to unexpected preclinical toxicity and need for additional preclinical work. With "limited cash runway and continued unpredictable effects of its anti-miR therapeutic candidates," the analyst sees continued overhang and need to monetize earlier pipeline assets to support a recovery in shares of Regulus. He keeps a Market Perform rating on the name.
03/27/18
RILY
03/27/18
INITIATION
Target $1
RILY
Neutral
Regulus initiated with a Neutral at B. Riley FBR
B. Riley FBR analyst Madhu Kumar started Regulus Therapeutics with a Neutral rating and $1 price target. The analyst believes the company is facing uncertainty in orphan kidney disease.

TODAY'S FREE FLY STORIES

SBUX

Starbucks

$66.67

0.57 (0.86%)

13:45
12/13/18
12/13
13:45
12/13/18
13:45
Hot Stocks
Starbucks CEO says customer behaviors shifting rapidly, company must adapt »

Starbucks CEO Kevin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

ADBE

Adobe

$245.82

0.38 (0.15%)

, COST

Costco

$225.99

-1.83 (-0.80%)

13:42
12/13/18
12/13
13:42
12/13/18
13:42
Earnings
Notable companies reporting after market close »

Notable companies…

ADBE

Adobe

$245.82

0.38 (0.15%)

COST

Costco

$225.99

-1.83 (-0.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 13

    Dec

SPY

SPDR S&P 500 ETF Trust

$264.81

-0.72 (-0.27%)

13:40
12/13/18
12/13
13:40
12/13/18
13:40
Options
Four-day hedge opened in SPYders »

Four-day hedge opened in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$109.16

-0.31 (-0.28%)

, LVS

Las Vegas Sands

$55.16

-0.3 (-0.54%)

13:36
12/13/18
12/13
13:36
12/13/18
13:36
Periodicals
Breaking Periodicals news story on Wynn Resorts, Las Vegas Sands »

Chanos shorting Wynn…

WYNN

Wynn Resorts

$109.16

-0.31 (-0.28%)

LVS

Las Vegas Sands

$55.16

-0.3 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JD

JD.com

$22.72

0.82 (3.74%)

13:30
12/13/18
12/13
13:30
12/13/18
13:30
Options
Call spreads in JD as shares gain 3.5% and a bullish position is adjusted »

Call spreads in JD as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIL

Hill International

$2.98

-0.11 (-3.56%)

13:29
12/13/18
12/13
13:29
12/13/18
13:29
Hot Stocks
Hill International selected by the ERBD to provide railway supervision services »

Hill International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBAI

Lakeland Bancorp

$14.83

-0.27 (-1.79%)

13:27
12/13/18
12/13
13:27
12/13/18
13:27
Hot Stocks
Highlands Bancorp investors approve merger with Lakeland Bancorp »

Lakeland Bancorp and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLSN

Nielsen

$25.70

-0.36 (-1.38%)

, BX

Blackstone

$30.22

-0.28 (-0.92%)

13:24
12/13/18
12/13
13:24
12/13/18
13:24
Periodicals
Nielsen to hold talks with potential buyers in January, CNBC says »

Nielsen (NLSN) intends to…

NLSN

Nielsen

$25.70

-0.36 (-1.38%)

BX

Blackstone

$30.22

-0.28 (-0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$66.44

-1.36 (-2.01%)

, WMT

Walmart

$92.78

-0.34 (-0.37%)

13:23
12/13/18
12/13
13:23
12/13/18
13:23
Hot Stocks
New York AG sues Target, Walmart over lead-contaminated toy sales »

New York Attorney General…

TGT

Target

$66.44

-1.36 (-2.01%)

WMT

Walmart

$92.78

-0.34 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

HIIQ

Health Insurance Innovations

$29.08

-0.985 (-3.28%)

13:21
12/13/18
12/13
13:21
12/13/18
13:21
Hot Stocks
Breaking Hot Stocks news story on Health Insurance Innovations »

Health Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

MET

MetLife

$39.30

-0.27 (-0.68%)

13:20
12/13/18
12/13
13:20
12/13/18
13:20
Options
Call buyer in MetLife lays out $57K for one-day trade »

Call buyer in MetLife…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

HIIQ

Health Insurance Innovations

$29.08

-0.985 (-3.28%)

13:20
12/13/18
12/13
13:20
12/13/18
13:20
Hot Stocks
Breaking Hot Stocks news story on Health Insurance Innovations »

Health Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
12/13/18
12/13
13:17
12/13/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
12/13/18
12/13
13:16
12/13/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MELI

MercadoLibre

$338.18

-23.4 (-6.47%)

13:15
12/13/18
12/13
13:15
12/13/18
13:15
Options
MercadoLibre put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
12/13/18
12/13
13:15
12/13/18
13:15
General news
Treasury's $16 B 30-year reopening was ok, but nothing special »

Treasury's $16 B…

13:15
12/13/18
12/13
13:15
12/13/18
13:15
General news
Treasury Action: yields tipped lower from highs »

Treasury Action: yields…

FB

Facebook

$143.95

-0.31 (-0.21%)

13:10
12/13/18
12/13
13:10
12/13/18
13:10
Hot Stocks
Facebook says Guardian did not utilize all information on fact-checking program »

Facebook Head of News…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:06
12/13/18
12/13
13:06
12/13/18
13:06
General news
30-Yr Bond Auction Coupon Rate data reported »

30-Yr Bond Auction Coupon…

13:06
12/13/18
12/13
13:06
12/13/18
13:06
General news
30-Yr Bond Auction Total Amount data reported »

30-Yr Bond Auction Total…

13:05
12/13/18
12/13
13:05
12/13/18
13:05
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

AEGN

Aegion

$17.61

-0.43 (-2.38%)

13:01
12/13/18
12/13
13:01
12/13/18
13:01
Hot Stocks
Aegion names Kenneth Young as controller »

Aegion Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$87.49

-1.13 (-1.28%)

13:00
12/13/18
12/13
13:00
12/13/18
13:00
Hot Stocks
AbbVie announces $5B boost to stock repurchase program »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIIQ

Health Insurance Innovations

$29.08

-0.985 (-3.28%)

12:59
12/13/18
12/13
12:59
12/13/18
12:59
Hot Stocks
Health Insurance Innovations boosts repurchase program to $100M from $50M »

Health Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HIIQ

Health Insurance Innovations

$29.08

-0.985 (-3.28%)

12:57
12/13/18
12/13
12:57
12/13/18
12:57
Hot Stocks
Health Insurance Innovations announces multistate settlement for $3.4M »

Health Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.